[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,828,078
  • Shares Outstanding, K 122,381
  • Annual Sales, $ 588,990 K
  • Annual Income, $ 214,330 K
  • EBIT $ 306 M
  • EBITDA $ 343 M
  • 60-Month Beta 0.72
  • Price/Sales 6.49
  • Price/Cash Flow 10.69
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 17.10% (-1.38%)
  • Historical Volatility 36.82%
  • IV Percentile 4%
  • IV Rank 3.81%
  • IV High 120.40% on 10/14/25
  • IV Low 13.01% on 05/12/26
  • Expected Move (DTE 26) 1.21 (3.86%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 489
  • Volume Avg (30-Day) 1,223
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 8,618
  • Open Int (30-Day) 12,322
  • Expected Range 30.05 to 32.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.63
  • Number of Estimates 2
  • High Estimate $0.68
  • Low Estimate $0.58
  • Prior Year $0.62
  • Growth Rate Est. (year over year) +1.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.89 +20.74%
on 04/23/26
32.56 -3.99%
on 04/27/26
+5.32 (+20.51%)
since 04/22/26
3-Month
22.16 +41.06%
on 03/20/26
32.56 -3.99%
on 04/27/26
+6.96 (+28.64%)
since 02/20/26
52-Week
19.05 +64.09%
on 09/25/25
32.56 -3.99%
on 04/27/26
+7.15 (+29.66%)
since 05/22/25

Most Recent Stories

More News
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 26.79 (+0.07%)
CPRX : 31.26 (-0.06%)
MDV : 18.24 (-0.16%)
GBTG : 9.44 (+0.11%)
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACR : 19.63 (+0.56%)
RMAX : 9.38 (-0.11%)
CPRX : 31.26 (-0.06%)
UNF : 265.47 (+0.26%)
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Delivered Q1 2026 Total Revenues  of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million...

CPRX : 31.26 (-0.06%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.26 (-0.06%)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals...

CPRX : 31.26 (-0.06%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.26 (-0.06%)
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACR : 19.63 (+0.56%)
TBRG : 25.94 (+0.15%)
CPRX : 31.26 (-0.06%)
MDV : 18.24 (-0.16%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.26 (-0.06%)
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 31.26 (-0.06%)
Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE   , May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Catalyst (NASDAQ: CPRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

CPRX : 31.26 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 31.35
2nd Resistance Point 31.33
1st Resistance Point 31.29
Last Price 31.26
1st Support Level 31.23
2nd Support Level 31.21
3rd Support Level 31.17

See More

52-Week High 32.56
Last Price 31.26
Fibonacci 61.8% 27.40
Fibonacci 50% 25.81
Fibonacci 38.2% 24.21
52-Week Low 19.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.